Diabetes

Researchers have focused on changes in the gut bacteria to figure out who is at risk for a loss of beta cell function.

Healthcare experts increasingly recognize that behavioral science will provide the ideas for reducing the $245 billion annual cost of diabetes in the United States.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

The US Preventive Services Task Force already has recommendations for screening and intervention for obesity, but they often are not followed.

Scaling behavioral change and reducing diabetes at the population level were major themes of the meeting.

This week, the top managed care stories included speculation regarding who would replace Tom Price, MD, as HHS secretary; a report on breast cancer mortality trends and racial disparities from 1989 to 2015; and the FDA announced new strategies to improve patient access to less expensive drugs.

The announcement does not affect LifeScan, which makes blood glucose management tools and apps. Company officials said an exclusivity deal between Medtronic and UnitedHealthcare was among the factors that contributed to the decision.

The fight for dominance of the market for a costly cholesterol drug continues, even as sales fall short of expectations.

CMS’ decision to exclude digital health from its proposal for the Medicare Diabetes Prevention Program (DPP) has caused a controversy, explained Paul Chew, MD, chief medical officer of Omada Health.

The review of 28 studies found that night shift workers were at particularly high risk of developing the type of abdominal obesity associated with heart disease.

The author, who has lived with type 1 diabetes for 16 years, offers practical advice on food, exercise, mindset, and sleep.

The filing also seeks new indications for fixed-dose combinations of canagliflozin and metformin.

This is the second year in a row that the prize in Medicine or Physiology has been awarded for work that yielded understanding of chronic disease.

The CEO said the changes will finally allow the company to set the inhaled insulin apart from its rivals.

The CDC reports that more than 30 million Americans have diabetes, and an analysis of new Gallup-Sharecare data on diabetes by occupation.

Three physicians presented results of CANVAS and CANVAS-R, as well as other studies, and invited questions about the use of canagliflozin in primary care.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.

A continuous glucose monitor (CGM) device made in the United States is finally approved for use here after patients in 40 other countries already have access.

HHS has challenged mobile app developers and other technology innovators to create an intervention to promote nutrition, health, and fitness among low-income children and families.

The FDA has announced the 9 companies that will participate in a pilot precertification program to speed the approval of digital health software.

The pilot program is the latest venture among stakeholders in diabetes care to look for ways to deploy patient data to improve outcomes and hold down costs.

The move to give entrepreneurs access to patient-approved continuous glucose monitoring data fits with the company's prediction that insulin pumps will become a thing of the past, and most of the heavy lifting of delivery will be done by a smartphone.

With 35% of Americans having prediabetes, prevention is clearly a priority, but many strategies have not bee translated into clinical practice because there is no system for reimbursement yet, explained Paul Chew, MD, chief medical officer of Omada Health